Cleared Traditional

K951709 - MARDX LYME DISEASE (IGM) MARBLOT STRIP TEST SYSTEM

K951709 is an FDA 510(k) clearance for MARDX LYME DISEASE (IGM) MARBLOT STRIP ..., manufactured by Mardx Diagnostics, Inc.. The device is a Class 2 Microbiology device with product code LSR cleared through the Traditional 510(k) pathway after a 421-day FDA review.

K951709 · Mardx Diagnostics, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1996
Decision
421d
Days
Class 2
Risk

K951709 is an FDA 510(k) clearance for the MARDX LYME DISEASE (IGM) MARBLOT STRIP TEST SYSTEM. Classified as Reagent, Borrelia Serological Reagent (product code LSR), Class II - Special Controls.

Submitted by Mardx Diagnostics, Inc. (Carlsbad, US). The FDA issued a Cleared decision on June 7, 1996 after a review of 421 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3830 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all Mardx Diagnostics, Inc. devices

FDA 510(k) Submission Details - K951709

510(k) Number K951709 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 13, 1995
Decision Date June 07, 1996
Days to Decision 421 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
319d slower than avg
Panel avg: 102d · This submission: 421d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LSR Device Classification - Class 2, Special Controls

Product Code LSR Reagent, Borrelia Serological Reagent
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3830
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - LSR Reagent, Borrelia Serological Reagent

All 90
Devices cleared under the same product code (LSR) and FDA review panel - the closest regulatory comparables to K951709.
ACCURUN(TM) 132 BORRELIA BURDORFERI IGM POSITIVE CONTROL
K974810 · Boston Biomedica, Inc. · Feb 1998
BORRELIA BURGDORFERI IGM ELISA TEST SYSTEM
K965129 · Wampole Laboratories · Mar 1997
BORRELIA BURGDORFERI IGG/IGM ELISA TEST SYSTEM
K965131 · Wampole Laboratories · Mar 1997
MARDX LYME DISEASE (IGG) MARBLOT STRIP TEST SYSTEM
K950829 · Mardx Diagnostics, Inc. · Jun 1996
IMMUNO DOT BORRELIA DOT BLOT G TEST
K953682 · Genbio · May 1996
MMUNO DOT BORRELIA DOT BLOT M TEST
K953683 · Genbio · May 1996